GEN-MKT-18-7897-A
Apr 17, 2025 | Blogs, Clinical | 0 comments
Read time: 4 minutes
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has gained significant attention in the clinical laboratory due to its ability to provide best-in-class sensitivity and specificity for the detection of clinically relevant analytes across a wide range of assays. For clinical laboratories new to LC-MS/MS, integrating this technology into their daily routine operations may seem like a daunting task. Developing a clear outline and defining the requirements needed to implement LC-MS/MS into your daily operations is critical to maximize the productivity and success of your clinical laboratory.
Below are four easy steps to follow to ensure a seamless integration of this new technology. Each step includes useful resources and considerations to help your laboratory prepare for the successful implementation of mass spectrometry.
Laboratory space readiness is the first step to successfully implementing LC-MS/MS in your laboratory’s operations. As you prepare to receive your new SCIEX instrument, consult your SCIEX preparation guide to ensure you have adequate infrastructure and space to meet the following requirements:
Step 2: Ensure the appropriate IT infrastructure is in place to support your laboratory’s operation
Determining the IT requirements for your SCIEX instruments and the data they generate is key to a successful implementation. Be sure you understand your IT requirements so you can have the necessary IT network and infrastructure in place to fully support the data you acquire. These requirements include:
Step 3: Bulletproof your laboratory with best-in-class service
Browse through our comprehensive service options to find which one fits your laboratory needs. Choose the right service options that meet the needs of your laboratory’s operations. Our flexible service offerings are meant to ensure your instruments are running at peak performance with optimal sensitivity so you can acquire reliable data you can trust. Consider the following key points when choosing the right service plan that fits your laboratory needs:
Step 4: Ensure continuous success of your laboratory with our flexible support offerings
Find the support options that fit the evolving needs of your laboratory. Our flexible support options are designed to provide the right level of support for your laboratory and its staff. Maximize the lifespan and daily performance of your systems to get the most from your technology investment with our best-in-class support options, which include:
For additional information about our IVD medical devices, software solutions, and service and support offerings, please visit our website or check out our clinical implementation guide.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network